Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Emerging Markets, Biosimilars May Enhance Suitors' Interest In ratiopharm

Executive Summary

More than a year after being put up for sale, German generics firm ratiopharm is now said to have three serious suitors: generics giant Teva, Iceland's Actavis and Pfizer

You may also be interested in...



Teva Wins Ratiopharm For $5 Billion And Gains A Key Foothold In Europe

Teva has emerged as the winner in a months-long bidding war for ratiopharm, Germany's second-largest generics manufacturer after Novartis's Sandoz unit

Teva Wins Ratiopharm For $5 Billion And Gains A Key Foothold In Europe

Teva has emerged as the winner in a months-long bidding war for ratiopharm, Germany's second-largest generics manufacturer after Novartis's Sandoz unit

Teva Wins Ratiopharm For $5 Billion, And Gains A Key Foothold In Europe

The acquisition makes Teva the leading generics company in Europe, which is a key to its ambitious plans for global growth.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS052028

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel